Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Consolidated Net Income (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of Consolidated Net Income readings, the most recent being $17.7 million for Q4 2025.

  • Quarterly Consolidated Net Income rose 273.98% to $17.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $71.8 million through Dec 2025, up 475.6% year-over-year, with the annual reading at $71.8 million for FY2025, 475.6% up from the prior year.
  • Consolidated Net Income hit $17.7 million in Q4 2025 for Oramed Pharmaceuticals, down from $48.4 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $48.4 million in Q3 2025 and bottomed at -$23.0 million in Q3 2021.
  • Average Consolidated Net Income over 5 years is -$531000.0, with a median of -$5.2 million recorded in 2023.
  • The largest annual shift saw Consolidated Net Income skyrocketed 800.99% in 2024 before it crashed 598.17% in 2025.
  • Oramed Pharmaceuticals' Consolidated Net Income stood at -$23.0 million in 2021, then surged by 46.69% to -$12.3 million in 2022, then soared by 208.49% to $13.3 million in 2023, then plummeted by 176.71% to -$10.2 million in 2024, then soared by 273.98% to $17.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Consolidated Net Income are $17.7 million (Q4 2025), $48.4 million (Q3 2025), and $13.3 million (Q2 2025).